Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this clinical trial publication.

Numerous barriers impede replacement, including malabsorption secondary to gut GVHD, mucositis, inability to take capsules, kidney disease, liver disease, and infection; many patients remain refractory despite vitamin D therapy.

The researchers hypothesized that a different formulation of cholecalciferol, administered on the tongue as a readily dissolving oral thin film (OTF), would ease administration and facilitate therapeutic vitamin D levels (>35 ng/mL) in patients who are refractory.

Who Took Part

According to the abstract, 20 patients were involved.

How the Study Was Run

The design is described as pilot.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

Numerous barriers impede replacement, including malabsorption secondary to gut GVHD, mucositis, inability to take capsules, kidney disease, liver disease, and infection; many patients remain refractory despite vitamin D therapy.

The researchers hypothesized that a different formulation of cholecalciferol, administered on the tongue as a readily dissolving oral thin film (OTF), would ease administration and facilitate therapeutic vitamin D levels (>35 ng/mL) in patients who are refractory.

PubMed files the paper under topics including Cholecalciferol, Graft vs Host Disease, Pilot Projects, Stem Cell Transplantation and Vitamin D.

What This Means in Plain Language

The paper is a pilot study of Vitamin D, K2, Magnesium and Zinc in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2023 (Blood advances), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.